Skip to main content
OpenTrials
Completed

NCT Number: NCT00147030

TOBY (TOtal Body hYpothermia): a Study of Treatment for Perinatal Asphyxia

Hypothesis: Prolonged whole body cooling in term infants with perinatal asphyxial encephalopathy reduces death and severe neurodevelopmental disability.

This study aims to determine whether whole body cooling to 33-34°C is a safe treatment that improves survival, without severe neurological or neurodevelopmental impairments at 18 months, of term infants suffering perinatal asphyxial encephalopathy.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This is a multicentre prospective randomised controlled trial to determine whether a reduction of body temperature by 3-4°C following perinatal asphyxia improves survival without neurodevelopmental disability.

Full term infants will be randomised within 6 hours of birth to either a control group with the rectal temperature kept at 37 ± 0.2°C or to whole body cooling with the rectal temperature kept at 33.5 ± 0.5°C for 72 hours followed by slow rewarming.

The outcome will be assessed at 18 months of age by survival and neurological and neurodevelopmental testing.

Eligibility criteria:

Term infants less than 6 hours after birth with moderate or severe perinatal asphyxia (a combination of clinical and EEG criteria).

Exclusion criteria

Infants expected to be 6 hours of age at the time of randomisation or infants with major congenital abnormalities.

Intervention:

Intensive care with whole body cooling versus intensive care without whole body cooling (babies are cooled to 33.5°C for 72 hours)

Main Outcomes:

Death and severe neurodevelopmental impairment at 18 months of age

Secondary Outcomes:

Cerebral thrombosis or haemorrhage, persistent hypotension, pulmonary hypertension, abnormal coagulation, arrhythmia and sepsis in the neonatal period. Neurological impairments at 18 months

Number of patients required: 236.

On 30th November 2006, when recruitment closed, 325 babies had been recruited.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The infant will be assessed sequentially by criteria A, B and C listed below:

A. Infants =>36 completed weeks gestation admitted to the Neonatal Intensive Care Unit (NICU) with at least one of the following:

  • Apgar score of =<5 at 10 minutes after birth
  • Continued need for resuscitation, including endotracheal or mask ventilation, at 10 minutes after birth
  • Acidosis within 60 minutes of birth (defined as any occurrence of umbilical cord, arterial or capillary pH <7.00)
  • Base Deficit =>16 mmol/L in umbilical cord or any blood sample (arterial, venous or capillary) within 60 minutes of birth

Infants that meet criteria A will be assessed for whether they meet the neurological abnormality entry criteria (B) by trained personnel:

B. Moderate to severe encephalopathy, consisting of altered state of consciousness (lethargy, stupor or coma) AND at least one of the following:

  • hypotonia
  • abnormal reflexes including oculomotor or pupillary abnormalities
  • absent or weak suck
  • clinical seizures

Infants that meet criteria A & B will be assessed by amplitude-integrated electroencephalogram (aEEG) (read by trained personnel):

C. At least 30 minutes duration of amplitude integrated EEG recording that shows abnormal background aEEG activity or seizures. There must be one of the following:

  • normal background with some seizure activity
  • moderately abnormal activity
  • suppressed activity
  • continuous seizure activity

Exclusion criteria

  • Infants expected to be > 6 hours of age at the time of randomisation
  • Major congenital abnormalities, such as diaphragmatic hernia requiring ventilation, or congenital abnormalities suggestive of chromosomal anomaly or other syndromes that include brain dysgenesis

Treatment and study plan

Whole body mild induced hypothermia

Procedure

Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia

Primary outcomes

  1. Combined Incidence of Mortality and Severe Neurodevelopmental Disability in Survivors

    Time frame: 18 months

    Severe neurodevelopmental disability was defined as a score of less than 70 on the Mental Developmental Index of the Bayley Scales of Infant Development II (BSID-II) (on which the standardization mean [± standard deviation (SD)] is 100±15 and higher scores indicate better performance), a score of 3 to 5 on the Gross Motor Function Classification System (GMFCS) (on which scores can range from 1 to 5, with higher scores indicating greater impairment), or bilateral cortical visual impairment with no useful vision.

Secondary outcomes

  1. Intracranial Haemorrhage

    Time frame: Duration of hospital stay, on average 22 days

    Intracranial hemorrhage was identified on magnetic resonance imaging (MRI).

  2. Persistent Hypotension

    Time frame: Duration of hospital stay, on average 22 days

    Hypotension was defined as a mean blood pressure of 40 mm Hg or less and was persistent if causes of hypotension had been sought and appropriate treatment provided, without success.

  3. Pulmonary Haemorrhage

    Time frame: Duration of hospital stay, on average 22 days

  4. Pulmonary Hypertension

    Time frame: Duration of hospital stay, on average 22 days

  5. Prolonged Blood Coagulation Time

    Time frame: Duration of hospital stay, on average 22 days

  6. Culture Proven Sepsis

    Time frame: Duration of hospital stay, on average 22 days

  7. Necrotising Enterocolitis

    Time frame: Duration of hospital stay, on average 22 days

  8. Cardiac Arrhythmia

    Time frame: Duration of hospital stay, on average 22 days

    Arrhythmia identified on electrocardiogram (ECG), e.g. sinus bradycardia <80 beats per minute, ventricular arrhythmia.

  9. Thrombocytopenia

    Time frame: Duration of hospital stay, on average 22 days

  10. Major Venous Thrombosis

    Time frame: Duration of hospital stay, on average 22 days

  11. Renal Failure Treated With Dialysis

    Time frame: Duration of hospital stay, on average 22 days

  12. Pneumonia

    Time frame: Before discharge from hospital

  13. Pulmonary Airleak

    Time frame: Duration of hospital stay, on average 22 days

  14. Duration of Hospitalisation

    Time frame: Duration of hospital stay, on average 22 days

    Total duration of hospital care

  15. Mortality

    Time frame: 18 months

  16. Severe Neurodevelopmental Disability

    Time frame: 18 months

  17. Multiple Handicap

    Time frame: 18 months

    defined as the presence of any two of the following in an infant; neuromotor disability (Level 3-5 on Gross Motor Function classification), mental delay (Bayley Mental Developmental Index (MDI) score < 70), epilepsy, cortical visual impairment, sensorineural hearing loss

  18. Bayley Psychomotor Developmental Index Score (PDI)

    Time frame: 18 months

    Bayley Psychomotor Developmental Index score (PDI) <70

  19. Sensorineural Hearing Loss

    Time frame: 18 months

    Normal or near normal hearing, no sensorineural hearing loss

  20. Epilepsy (Defined as Recurrent Seizures Beyond the Neonatal Period, Requiring Anticonvulsant Therapy at the Time of Assessment)

    Time frame: 18 months

  21. Microcephaly

    Time frame: 18 months

    Head circumference at follow-up >2 standard deviations below the mean

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Collaborators

  • Medical Research Council

Registry information

Official study title

Whole Body Hypothermia for the Treatment of Perinatal Asphyxial Encephalopathy

Important dates

Study start
2002
Primary completion
2006
Study completion
2008
First posted
Sep 7, 2005
Registry last updated
May 11, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.